Evidence map›Paper›PMID 42108570›Full record

ArticleCancer medicine2026

Neutrophil Elastase as a Prognostic Biomarker and Driver of Tumor Progression in Diffuse Large B-Cell Lymphoma.

Xinyu Zheng, Lingling Wang, Ziqi Liu, Yunye Qiu, Jinbo Lu, Ling Shu, Chuanhai Xu, Meiling Zhou, Yuqing Miao, Yuexin Cheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xinyu ZhengCancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China.ORCID https://orcid.org/0009-0004-0270-5335
Lingling WangDepartment of Hematology, Yancheng First People's Hospital, Yancheng, China.
Ziqi LiuCancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Yunye QiuCancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Jinbo LuDepartment of Hematology, Yancheng First People's Hospital, Yancheng, China.
Ling ShuDepartment of Hematology, Yancheng First People's Hospital, Yancheng, China.
Chuanhai XuDepartment of Pathology, Yancheng First People's Hospital, Yancheng, China.
Meiling ZhouDepartment of Hematology, Yancheng First People's Hospital, Yancheng, China.
Yuqing MiaoCancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Yuexin ChengCancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China.

Funding

Yuexin Cheng XZSYSKF2025009Yuexin Cheng YCBE202558
6 · The paper itself

Abstract

introductionWith increasing recognition of the prognostic role of neutrophils in malignancies, this study investigated the clinical significance of neutrophil elastase (NE) expression in diffuse large B-cell lymphoma (DLBCL).

methodsEighty-seven patients with newly diagnosed primary DLBCL treated at Yancheng First People's Hospital between June 2020 and September 2024 were included. NE expression in tumor tissues was assessed by immunohistochemistry. Clinical and pathological characteristics were compared between NE-positive (NE

resultsPositive NE expression was detected in 51.7% of DLBCL specimens. Compared with the NE

conclusionNE expression is associated with an unfavorable prognosis in DLBCL and may serve as a potential prognostic biomarker. Moreover, NE promotes lymphoma cell proliferation and inhibits apoptosis, effects that can be effectively reversed by sivelestat.

Indexed as

Biomarkers, TumorLeukocyte ElastaseLymphoma, Large B-Cell, DiffuseAdultAgedApoptosisCell Line, TumorCell ProliferationDisease ProgressionFemaleGlycineHumansMaleMiddle AgedPrognosisSulfonamidesBiomarkers, TumorGlycineLeukocyte ElastasesivelestatSulfonamidesdiffuse large B‐cell lymphomaneutrophil elastaseprognosissivelestat

Identifiers

PMID42108570
PMCPMC13158270

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.